bexagliflozin + verapamil

Bexagliflozin + verapamil is a hypothetical combination drug consisting of bexagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor used in type 2 diabetes, and verapamil, a non-dihydropyridine calcium channel blocker primarily indicated for hypertension, angina, and arrhythmia. - **Bexagliflozin** reduces renal glucose reabsorption by inhibiting SGLT2, thus lowering the renal threshold for glucose and increasing urinary glucose excretion[1][7]. - **Verapamil** blocks L-type (and to some extent T-type) calcium channels in myocardial and vascular smooth muscle, leading to vasodilation and decreased cardiac contractility, with additional effects including antihypertensive, antiarrhythmic, and potential β-cell protective activity[2][3][4]. No approved combination formulation of these two agents currently exists. There are no published products, code names, or branded combinations for bexagliflozin + verapamil.